Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Official Title

Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors

Details

Keywords

Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1, Neoplasms, Neuroendocrine Tumors, Carcinoid Tumor, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Malignant Carcinoid Syndrome, Gastrointestinal Neoplasms, Biospecimen Collection, Computed Tomography, Echocardiography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Quality-of-Life Assessment, X-Ray Imaging

Eligibility

Locations

  • UCSF Medical Center-Mount Zion
    San Francisco California 94115 United States
  • UCSF Medical Center-Mission Bay
    San Francisco California 94158 United States
  • Palo Alto Medical Foundation Health Care
    Palo Alto California 94301 United States
  • Stanford Cancer Institute Palo Alto
    Palo Alto California 94304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT01841736
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 171 people participating
Last Updated